First-line cetuximab versus bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a systematic review and meta-analysis

Table 5 Outcomes for meta analysis of RCTs

Outcomes	study	Number for patients		Heterogeneity(I²)	RR/HR	95%CI	P Value
Outcomes	study	Cetuximab	bevacizumab	Heterogeneity(I²)	RR/HR	95%CI	P Value
Objective response rate	2 RCTs	529	480	0%	1.08	0.99–1.17	0.07
Disease control rate	1 RCT	237	256	–	0.92	0.86–0.99	0.02
Complete response	1 RCT	297	295	–	3.23	1.06–9.79	0.04
Partial response	1 RCT	171	167	–	1.02	0.88–1.17	0.81
Stable disease	1 RCT	297	295	–	0.62	0.46–0.84	0.002
Progressive disease	1 RCT	297	295	–	1.30	0.69–2.45	0.41
Early objective response rate	1 RCT	157	173	–	1.40	1.16–1.68	0.0004
Hematologic Adverse Events	1 RCT	578	559	–	1.05	0.88–1.26	0.58
Nonhematologic Adverse Events	1 RCT	578	559	–	1.17	0.79–1.72	0.43
Curative intent metastasectomy	1 RCT	578	559	–	1.29	0.98–1.71	0.07
Overall survival	2 RCTs	875	854	20%	0.86	0.76–0.96	0.007
Progression free survival	2 RCTs	875	854	19%	0.97	0.88–1.06	0.44

ISSN: 1471-2407